Vistagen to Present at Stifel 2023 Healthcare Conference
08 November 2023 - 2:30PM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression, and other central nervous system
(CNS) disorders, today announced that company management will
present and host one-on-one meetings at the Stifel 2023 Healthcare
Conference taking place November 14 – 15, 2023 at the Lotte New
York Palace Hotel in New York City.
Stifel 2023 Healthcare Conference
- Shawn Singh, Vistagen CEO, will provide a corporate overview on
Tuesday, November 14 at 1:15 p.m. Eastern Time.
A webcast will be accessible through the “Events” page in the
“Investors” section of the Company’s website at www.Vistagen.com.
Investors interested in arranging a one-on-one meeting during the
conference should contact their Stifel representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression, and
other CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those currently available for the treatment
of anxiety, depression, and multiple CNS disorders. Vistagen's
pipeline contains six clinical-stage product candidates, including
fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an
investigational agent belonging to a new class of drugs known as
pherines, as well as AV-101, which is an oral prodrug of an
antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines
are neuroactive nasal sprays designed with an innovative proposed
mechanism of action that activates chemosensory neurons in the
nasal cavity and can beneficially impact key neural circuits in the
brain without systemic absorption or direct activity on neurons in
the brain. Vistagen is passionate about transforming mental health
care and redefining what is possible in the treatment of anxiety,
depression, and several other CNS disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108051546/en/
Investors: Mark McPartland Senior Vice President, Investor
Relations (650) 577-3606 markmcp@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024